Jubilant Life Sciences is currently trading at Rs. 562.75, up by 21.45 points or 3.96% from its previous closing of Rs. 541.30 on the BSE.
The scrip opened at Rs. 545.05 and has touched a high and low of Rs. 575.25 and Rs. 545.05 respectively. So far 55013 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 18-Mar-2019 and a 52 week low of Rs. 392.30 on 26-Aug-2019.
Last one week high and low of the scrip stood at Rs. 575.25 and Rs. 468.00 respectively. The current market cap of the company is Rs. 9043.19 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 29.81% and 19.52% respectively.
Jubilant Life Sciences’ material wholly owned subsidiary — Jubilant Pharma through one of its wholly owned subsidiaries has received Abbreviated New Drug Application (ANDA) final approval for Clomipramine Hydrochloride Capsules USP 25mg, 50mg and 75mg, the generic version of Anafranil of SpecGx LLC, which is used for the treatment of obsessions and compulsions in patients with Obsessive- Compulsive Disorder (OCD).
As on June 30, 2019, Jubilant had a total of 96 ANDAs for Oral Solids filed in the US, of which 61 had been approved and 15 Injectable filings, of which 13 had been approved.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.